Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Histone deacetylase: a potential therapeutic target for fibrotic disorders.

Literature DB >> 20719940

Histone deacetylase: a potential therapeutic target for fibrotic disorders.

Abstract

Histone deacetylases (HDACs) are enzymes that balance the acetylation activities of histone acetyltransferases on chromatin remodeling and play essential roles in regulating gene transcription. In the past several years, the role of HDACs in cancer initiation and progression, as well as the therapeutic effects of HDAC inhibitors in various types of cancer, has been well studied. Recent studies indicated that HDAC activity is also associated with the development and progression of some chronic diseases characterized by fibrosis, including chronic kidney disease, cardiac hypertrophy, and idiopathic pulmonary fibrosis. Here, we review what is known about HDACs in the progression of tissue fibrosis and the potential applications of HDAC inhibitors in the treatment of disorders associated with fibroblast activation and proliferation.

Entities: Disease

Mesh：

Substances：

Year: 2010 PMID： 20719940 PMCID： PMC2967408 DOI： 10.1124/jpet.110.168385

Source DB: PubMed Journal: J Pharmacol Exp Ther ISSN： 0022-3565 Impact factor: 4.030

80 in total

1. Signal transducer and activator of transcription 3 involvement in the development of renal interstitial fibrosis after unilateral ureteral obstruction.

Authors: Masatoshi Kuratsune; Takao Masaki; Takayuki Hirai; Kei Kiribayashi; Yukio Yokoyama; Tetsuji Arakawa; Noriaki Yorioka; Nobuoki Kohno
Journal: Nephrology (Carlton) Date: 2007-12 Impact factor: 2.506

2. Enhanced histone deacetylase enzyme activity in primary myelofibrosis.

Authors: Jen Chin Wang; Chi Chen; Theresa Dumlao; Seema Naik; Thong Chang; Ying-Yi Xiao; Inna Sominsky; Jack Burton
Journal: Leuk Lymphoma Date: 2008-12

Review 3. Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders.

Authors: Norbert L Wiech; Jed F Fisher; Paul Helquist; Olaf Wiest
Journal: Curr Top Med Chem Date: 2009 Impact factor: 3.295

4. Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin.

Authors: Fang Liu; Mark D Levin; Nataliya B Petrenko; Min Min Lu; Tao Wang; Li Jun Yuan; Andrea L Stout; Jonathan A Epstein; Vickas V Patel
Journal: J Mol Cell Cardiol Date: 2008-09-16 Impact factor: 5.000

5. Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis.

Authors: Hossein Hemmatazad; Hanna Maciejewska Rodrigues; Britta Maurer; Fabia Brentano; Margarita Pileckyte; Jörg H W Distler; Renate E Gay; Beat A Michel; Steffen Gay; Lars C Huber; Oliver Distler; Astrid Jüngel
Journal: Arthritis Rheum Date: 2009-05

6. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines.

Authors: Maria G Catalano; Roberta Poli; Mariateresa Pugliese; Nicoletta Fortunati; Giuseppe Boccuzzi
Journal: Endocr Relat Cancer Date: 2007-09 Impact factor: 5.678

7. Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation.

Authors: Wendy Glenisson; Vincent Castronovo; David Waltregny
Journal: Biochim Biophys Acta Date: 2007-06-12

Review 8. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.

Authors: Jennifer S Carew; Francis J Giles; Steffan T Nawrocki
Journal: Cancer Lett Date: 2008-05-06 Impact factor: 8.679

9. Activation of signal transducer and activator of transcription 3 correlates with cell proliferation and renal injury in human glomerulonephritis.

Authors: Tetsuji Arakawa; Takao Masaki; Takayuki Hirai; Shigehiro Doi; Masatoshi Kuratsune; Koji Arihiro; Nobuoki Kohno; Noriaki Yorioka
Journal: Nephrol Dial Transplant Date: 2008-06-13 Impact factor: 5.992

10. The epigenetic signature of CFTR expression is co-ordinated via chromatin acetylation through a complex intronic element.

Authors: Thankam Paul; SiDe Li; Sanjeev Khurana; Neal S Leleiko; Martin J Walsh
Journal: Biochem J Date: 2007-12-15 Impact factor: 3.857

74 in total

1. Serum concentrations of cyclooxygenase-2 in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis.

Authors: Iman H Bassyouni; Roba M Talaat; Tarek A Salem
Journal: J Clin Immunol Date: 2011-10-07 Impact factor: 8.317

Review 2. Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.

Authors: Giovanni Barosi
Journal: Curr Hematol Malig Rep Date: 2015-12 Impact factor: 3.952

3. Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic type 2 inflammation.

Authors: Zhixuan Loh; Rebecca L Fitzsimmons; Robert C Reid; Divya Ramnath; Andrew Clouston; Praveer K Gupta; Katharine M Irvine; Elizabeth E Powell; Kate Schroder; Jennifer L Stow; Matthew J Sweet; David P Fairlie; Abishek Iyer
Journal: Br J Pharmacol Date: 2019-08-17 Impact factor: 8.739

4. Histone acetyltransferase inhibitor C646 reverses epithelial to mesenchymal transition of human peritoneal mesothelial cells via blocking TGF-β1/Smad3 signaling pathway in vitro.

Authors: Yiya Yang; Kanghan Liu; Yumei Liang; Yinyin Chen; Ying Chen; Yuting Gong
Journal: Int J Clin Exp Pathol Date: 2015-03-01